FORM 5
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[ X ] Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response...
1.0
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Youkilis Eugene

2. Issuer Name and Ticker or Trading Symbol

Immune Therapeutics, Inc. [IMUN]

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
PRESIDENT

(Last)          (First)          (Middle)

37 NORTH ORANGE AVENUE,  SUITE 607

3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY)
12/31/2014 
(Street)

ORLANDO, FL 32801

(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person


Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Amount (A) or (D) Price
COMMON STOCK   9/30/2014     J4   (1) 88683   A $0.25   1088683   D    
COMMON STOCK   12/23/2014     J4   (2) 33125   A   (2) 1121808   D    

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YYYY)
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
(A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Inadvertently omitted filing Form 4 for September 30, 2014 transaction. The reporting person acquired these shares in full satisfaction of a $22,170.78 balance owed in connection with the reporting person's employment as president of the issuer.
( 2)  Inadvertently omitted filing Form 4 for December 23, 2014 transaction. The reporting person acquired these shares from the Nicholas P. Plotnikoff Family Trust pursuant to a Second Amended Plan of Liquidation approved by the U.S. Bankruptcy Court for the District of Delaware due to the reporting person's status as an unsecured creditor.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Youkilis Eugene
37 NORTH ORANGE AVENUE
SUITE 607
ORLANDO, FL 32801
X
PRESIDENT

Signatures
KIRSTEN BARTHOLOMEW, AUTHORIZED REPRESENTATIVE UNDER POWER OF ATTORNEY 2/12/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Immune Therapeutics (PK) Charts.
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Immune Therapeutics (PK) Charts.